

UNITED STATES BANKRUPTCY COURT DISTRICT OF NEW JERSEY	
Caption in Compliance with D.N.J. LBR 9004-1(b) HELLRING LINDEMAN GOLDSTEIN & SIEGAL LLP Patricia A. Staiano, Esq. Attorneys for Mediator One Gateway Center Newark, New Jersey 07102-5323 973.621.9020 <a href="mailto:pstaiano@hlglaw.com">pstaiano@hlglaw.com</a>	
In Re:	Case No. 19-13273 (VFP)
IMMUNE PHARMACEUTICALS, INC., et al., <sup>1</sup>	Judge: Vincent F. Papalia
Debtor.	Chapter 11
IMMUNE PHARMACEUTICALS, INC., IMMUNE PHARMACEUTICALS, LTD, CYTOVIA, INC., IMMUNE ONCOLOGY PHARMACEUTICALS, INC., MAXIM PHARMACEUTICALS, INC., IMMUNE PHARMACEUTICALS USA CORP,	Adversary No. 19-02033-VFP
Plaintiffs,	
v.	
Discover Growth Fund, LLC,	
Defendants.	

### **MEDIATION REPORT**

1. By order of this court dated February 27, 2020, referring this matter to the bankruptcy mediation program, a mediation conference(s):

☒ was held on *[list date(s) of conferences(s)]*:

Phone conferences - 2/21/20

Phone conferences - 2/28/20

---

<sup>1</sup> The Debtors in these chapter 11 cases and the last four digits of each Debtor's taxpayer identification number are as follows: Immune Pharmaceuticals, Inc. (1431); Immune Pharmaceuticals, Ltd.; Cytovia, Inc. (7805); Immune Oncology Pharmaceuticals, Inc.; Maxim Pharmaceuticals, Inc. (9983); and Immune Pharmaceuticals USA Corp. (9630).

Phone conferences - 3/4/20

Phone conferences - 3/11/20

☐ was not held.

2. A settlement of this matter:

☐ was reached ☒ was not reached

3. *[If a settlement was reached:]* The party designated to file the settlement documents(s) is, .

March 16, 2020

Date

/s/ Patricia A. Staiano

Mediator's Signature: PATRICIA A. STAIANO